GLP-1 Receptor Agonists and Pregnancy: What Recent Research Says About Fetal and Maternal Outcomes

The rise of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—popularly known for treating type 2 diabetes and obesity—has led to an increase in these medications being used, sometimes inadvertently, during pregnancy. For patients and providers, the primary concern is whether exposure to these drugs impacts the developing fetus or the health of the mother.

Recent systematic reviews and meta-analyses suggest that inadvertent GLP-1 RA exposure during pregnancy is not linked to an increased risk of preterm birth or major congenital malformations. In some instances, the data even indicates improved maternal outcomes.

What Are GLP-1 Receptor Agonists?

GLP-1 RAs are peptide analogues designed to treat obesity and type 2 diabetes mellitus. First introduced in 2005 with the approval of exenatide, the class has expanded to include medications like semaglutide, which have gained significant popularity due to their ability to improve cardiovascular health, reduce weight, and provide pronounced glycemic control ([AJOG]).

Impact on Fetal Development and Birth Outcomes

A comprehensive systematic review and meta-analysis of studies published between 2020 and 2025 evaluated the complications associated with GLP-1 RA exposure during preconception or the first trimester. The findings indicate that there are no statistically significant differences in several key pregnancy outcomes when comparing GLP-1 RA exposure to control groups:

• Preterm Delivery: No significant difference was found (p = 0.62).
• Major Birth Defects: No significant difference was observed (p = 0.79).
• Fetal Growth: There were no statistically significant differences regarding compact for gestational age or fetal growth restriction (p = 0.12).
• Miscarriages and Stillbirths: No significant differences were linked to miscarriages (p = 0.41) or stillbirths (p = 0.09).

Interestingly, the research found that GLP-1 RAs were linked to a lower risk of congenital heart defects (p = 0.03), a finding that remained consistent even in subgroup analyses focusing on first-trimester exposure ([PubMed]).

Maternal Health and Pregnancy Complications

Beyond fetal outcomes, research indicates that GLP-1 RA exposure may actually be associated with improved maternal and preterm birth outcomes ([JACC Advances]). However, the medications did not show a significant protective effect against the development of gestational diabetes (p = 0.49) ([ScienceDirect]).

Frequently Asked Questions

Does using GLP-1 RAs during pregnancy cause birth defects?

According to a systematic review of RCTs and cohort studies, there is no statistically significant increase in major birth defects (p = 0.79) associated with GLP-1 RA exposure ([PubMed]).

Is there a risk of the baby being born too early?

Current evidence suggests that GLP-1 RA employ is not linked to an increased risk of preterm delivery. In fact, some research indicates improved preterm birth outcomes ([JACC Advances]).

Do these medications help prevent gestational diabetes?

No. Research indicates that GLP-1 RAs do not provide a significant protective effect against gestational diabetes (p = 0.49) ([ScienceDirect]).

Looking Ahead

While current meta-analyses provide reassurance regarding the safety of inadvertent GLP-1 RA exposure, the marked increase in the use of these agents among pregnant patients highlights the need for ongoing surveillance. As more long-term data becomes available, clinicians will be better equipped to manage the intersection of obesity and diabetes treatments with prenatal care.